Trade Summary

3 days ago, Wiley Matthew T., serving as Chief Commercial Officer at Definium Therapeutics, Inc. (DFTX), sold 2,867 shares at $45.03 per share, for a total transaction value of $129,101.01. Following this transaction, Wiley Matthew T. now holds 174,633 shares of DFTX.

This sale represents a 1.62% decrease in Wiley Matthew T.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, June 25, 2026 and publicly disclosed via SEC Form 4 filing on Friday, June 26, 2026 at 4:30 PM ET, 1 day after the trade was made.

Definium Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.